Biweekly intravenous administration of Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus (VV), in CRC has been shown safe and well-tolerated.2 Pexa-Vec is currently being tested combined with durvalumab, an anti-PD-L1 agent, in phase I and with tremelimumab, anti-CTLA-4 antibody, in phase II in patients with refractory metastatic CRC (NCT03206073). Here, CD274 is linked to colorectal carcinoma.